Search Browse Earnings

BridgeBio Oncology Therapeutics, Inc.

Nasdaq:BBOT

Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

BridgeBio Oncology Therapeutics, Inc. — SlamSEC

Revenue

—

Adj. EBITDA

-$80.7M

FY 2025

Net Income

-$74.3M

FY 2025

EPS (Diluted)

-$5756.41

FY 2025

Stock Price

$10.18

-1.4%

2026-03-10

52W Range

$8.50 – $14.87

P/E Ratio

-0.0x

Market Cap

$815.0M

Cash

$30.9M

FY 2025

Total Debt

$483,000

FY 2025

Net Cash

$30.4M

FY 2025

Enterprise Value

$784.6M

Debt / EBITDA

0.4x

FY 2025

EV / EBITDA

-9.7x

Employees

—